• FY2026 revenue increased by 507% to $1,428,231
• The Group reported a loss after tax of $6,340,000
• The Group achieved a significant increase in customer receipts
• The Group continued to invest in product development and commercialisation
• The Group strengthened its capital position through the exercise of employee and investor options

Singular Health Group Limited reported strong revenue growth for the year ended 30 June 2026, with revenues increasing to $1,428,238 from $235,393 in FY2025. Despite this growth, the Group reported a loss after tax of $6,340,453. The Group achieved a significant increase in customer receipts during the second half of the financial year, supported by the contracted US$500,000 licence payment received from Provider Network Solutions (PNS). The Group continued to invest in the development and commercialisation of its 3DICOM platform while maintaining a disciplined approach to capital management. Investment throughout the year was directed towards product development, expansion of enterprise interoperability capabilities, regulatory compliance, commercial execution, and the organisational capability required to support the Group's growing U.S. customer base.

The Group remains focused on expanding market adoption of its technology.